Microfluidic single-cell transcriptional analysis rationally identifies novel surface marker profiles to enhance cell-based therapies
Citations Over TimeTop 10% of 2016 papers
Abstract
Current progenitor cell therapies have only modest efficacy, which has limited their clinical adoption. This may be the result of a cellular heterogeneity that decreases the number of functional progenitors delivered to diseased tissue, and prevents correction of underlying pathologic cell population disruptions. Here, we develop a high-resolution method of identifying phenotypically distinct progenitor cell subpopulations via single-cell transcriptional analysis and advanced bioinformatics. When combined with high-throughput cell surface marker screening, this approach facilitates the rational selection of surface markers for prospective isolation of cell subpopulations with desired transcriptional profiles. We establish the usefulness of this platform in costly and highly morbid diabetic wounds by identifying a subpopulation of progenitor cells that is dysfunctional in the diabetic state, and normalizes diabetic wound healing rates following allogeneic application. We believe this work presents a logical framework for the development of targeted cell therapies that can be customized to any clinical application.
Related Papers
- → Beta-Catenin Signaling Negatively Regulates Intermediate Progenitor Population Numbers in the Developing Cortex(2010)74 cited
- → Pancreatic Progenitor Cells—Recent Studies(2008)25 cited
- → Tcf7l1 is required for spinal cord progenitor maintenance(2011)11 cited
- → Neural progenitors and stem cells: mechanisms of progenitor heterogeneity(1998)93 cited
- → Defining the contribution of Troy -positive progenitor cells to the mouse esophageal epithelium(2024)1 cited